Thermo Fisher Scientific Inc. $TMO Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,980 shares of the medical research company’s stock after purchasing an additional 2,050 shares during the period. TD Waterhouse Canada Inc.’s holdings in Thermo Fisher Scientific were worth $18,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC grew its holdings in Thermo Fisher Scientific by 45.5% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 5,500 shares of the medical research company’s stock valued at $2,668,000 after buying an additional 1,719 shares in the last quarter. Field & Main Bank grew its holdings in shares of Thermo Fisher Scientific by 7.7% in the third quarter. Field & Main Bank now owns 1,922 shares of the medical research company’s stock valued at $932,000 after purchasing an additional 138 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Thermo Fisher Scientific by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 71,387 shares of the medical research company’s stock worth $34,624,000 after purchasing an additional 12,564 shares during the period. Bank of New York Mellon Corp boosted its holdings in Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares during the last quarter. Finally, Ballentine Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 12.5% during the 3rd quarter. Ballentine Partners LLC now owns 7,526 shares of the medical research company’s stock worth $3,650,000 after buying an additional 836 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $593.16 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a fifty day simple moving average of $594.14 and a two-hundred day simple moving average of $536.01. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a market cap of $222.86 billion, a price-to-earnings ratio of 34.27, a price-to-earnings-growth ratio of 3.99 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.44 by $0.13. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were issued a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This represents a 36.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Frederick M. Lowery sold 6,913 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. This trade represents a 32.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 124,517 shares of company stock worth $72,363,568. Insiders own 0.33% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat street estimates — Thermo Fisher reported adjusted EPS of $6.57 and revenue of about $12.21B (both above consensus), driven by life‑sciences tools and services demand. This underscores resilient end‑market demand for drug‑development tools. BusinessWire: Q4 and FY2025 Results
• Positive Sentiment: Top‑line momentum — Q4 sales grew ~7% year‑over‑year and full‑year revenue rose ~4%, highlighting steady commercial activity in life‑sciences and pharma services that supports medium‑term growth. Reuters: Beats on Demand from Pharma Clients
• Positive Sentiment: M&A accretion preview — Management disclosed expected EPS contribution from the Clario acquisition, signaling that recent M&A could be meaningfully accretive to future earnings as integration progresses. Benzinga: Clario Deal EPS Impact
• Positive Sentiment: Analyst support remains — Some sell‑side analysts (e.g., William Blair) kept Buy ratings, citing resilient organic growth and stabilizing end markets, which provides some near‑term investor support. TipRanks: Analyst Buy Rating
• Neutral Sentiment: Management commentary available — The full earnings‑call transcript provides details on end‑market trends, margin drivers and capex priorities for 2026; useful for investors modeling revenue mix and cost dynamics. Seeking Alpha: Earnings Call Transcript
• Neutral Sentiment: Valuation context — Recent share‑price momentum prompted fresh valuation checks; longer‑term investors should weigh the company’s premium multiple vs. steady cash flow and M&A optionality. Yahoo Finance: Valuation Check
• Negative Sentiment: Cautious 2026 outlook — Thermo Fisher guided 2026 revenue to $46.3B–$47.2B (about 4%–6% growth; organic ~3%–4%). Investors zeroed in on cautious profit guidance and margin pressures, which pressured the shares despite the beat. Proactive: Stock Slides on Cautious Guidance
• Negative Sentiment: Margin concerns highlighted — Commentary and coverage note near‑term margin headwinds (cost and mix effects) that temper upside to EPS even with revenue growth, a key reason for the stock’s downward move. MSN: Slips After Outlook Update

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. Leerink Partners increased their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Evercore ISI reissued an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Hsbc Global Res raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $625.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.